Jean M. Connors
A5061711123- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- COVID-19 Clinical Research Studies
- Mechanical Circulatory Support Devices
- COVID-19 and healthcare impacts
- Blood Coagulation and Thrombosis Mechanisms
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiac Structural Anomalies and Repair
- Central Venous Catheters and Hemodialysis
- Long-Term Effects of COVID-19
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Cardiac Arrhythmias and Treatments
- Platelet Disorders and Treatments
- Cardiac Arrest and Resuscitation
- Heart Failure Treatment and Management
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cardiac tumors and thrombi
- Sepsis Diagnosis and Treatment
- Hemophilia Treatment and Research
- Acute Ischemic Stroke Management
- Intramuscular injections and effects
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Case Reports on Hematomas
- Cancer Treatment and Pharmacology
Brigham and Women's Hospital
2016-2025
Harvard University
2016-2025
Dana-Farber Cancer Institute
2014-2024
Dana-Farber Brigham Cancer Center
2011-2023
Juntendo University
2020
University College London
2020
Bristol-Myers Squibb (Germany)
2020
Abbott (United Kingdom)
2020
Manchester Royal Infirmary
2020
University College London Hospitals NHS Foundation Trust
2020
Recent guidelines recommend consideration of the use oral edoxaban or rivaroxaban for treatment venous thromboembolism in patients with cancer. However, benefit these agents is limited by increased risk bleeding associated their use.This was a multinational, randomized, investigator-initiated, open-label, noninferiority trial blinded central outcome adjudication. We randomly assigned consecutive cancer who had symptomatic incidental acute proximal deep-vein thrombosis pulmonary embolism to...
The antiplatelet drug clopidogrel is a new thienopyridine derivative whose mechanism of action and chemical structure are similar to those ticlopidine. estimated incidence ticlopidine-associated thrombotic thrombocytopenic purpura 1 per 1600 5000 patients treated, whereas no clopidogrel-associated cases were observed among 20,000 closely monitored treated in phase 3 clinical trials cohort studies. Because the association between ticlopidine use other adverse effects, has largely replaced...
Summary The optimal management of asparaginase‐associated thrombotic complications is not well‐defined. We report the features, and outcome paediatric (ages 0–18 years) adult (18–50 patients with acute lymphoblastic leukaemia (ALL) asparaginase‐related venous thromboembolic events (VTE) treated at Dana‐Farber Cancer Institute on clinical trials for newly diagnosed ALL between 1991–2008. Of 548 patients, 43 (8%) had VTE, including 27/501 (5%) 16/47 (34%) patients. Sinus thrombosis occurred in...
<h3>Importance</h3> Acutely ill inpatients with COVID-19 typically receive antithrombotic therapy, although the risks and benefits of this intervention among outpatients have not been established. <h3>Objective</h3> To assess whether anticoagulant or antiplatelet therapy can safely reduce major adverse cardiopulmonary outcomes symptomatic but clinically stable COVID-19. <h3>Design, Setting, Participants</h3> The ACTIV-4B Outpatient Thrombosis Prevention Trial was designed as a...
In patients with cancer who have venous thromboembolism (VTE) events, long-term anticoagulation low-molecular-weight heparin (LMWH) is recommended to prevent recurrent VTE. The effectiveness of a direct oral anticoagulant (DOAC) compared LMWH for preventing VTE in uncertain.To evaluate DOACs, LMWH, and rates bleeding following an initial event.Unblinded, comparative effectiveness, noninferiority randomized clinical trial conducted at 67 oncology practices the US that enrolled 671 (any...
The efficacy and safety of prophylactic full-dose anticoagulation antiplatelet therapy in critically ill COVID-19 patients remain uncertain.COVID-PACT (Prevention Arteriovenous Thrombotic Events Critically-ill Patients Trial) was a multicenter, 2×2 factorial, open-label, randomized-controlled trial with blinded end point adjudication intensive care unit-level COVID-19. were randomly assigned to strategy or standard-dose anticoagulation. Absent an indication for therapy, additionally either...